When during a course of treatment is gilteritinib used to treat FLT3 positive AML?

Gilteritinib is

now being used only in the setting
of relapsed and refractory acute myeloid leukemia.

That's where it's approved.

Relapsed and refractory
means that you had leukemia, you got treatment,

and the treatment didn't work or you had leukemia,
you got treatment.,

the leukemia went into remission,
but then it came back down the road.

So that's what gilteritinib is currently approved.

And there are some exciting clinical studies
that are looking at the use of gilteritinib

in combination with chemotherapy
for newly diagnosed acute myeloid leukemia.

You know, whenever you have a good drug

that's being used in the relapse and refractory
setting, you know, we don't want to keep it there.

We want to give our best drugs
at the very beginning of treatment.

So this clinical trial's looking to see
does gilteritinib in combination

with chemotherapy work
better than chemotherapy in combination

with what's called a first generation or a less
potent FLT3 inhibitor called midostaurin.

with what's called a first generation or a less
potent FLT3 inhibitor called midostaurin.

So gilteritinib is appropriate for anyone with a
FLT3 mutation who has relapsed and refractory AML.

So gilteritinib is appropriate for anyone with a
FLT3 mutation who has relapsed and refractory AML.

I mean, that is what a patient in 2022 should get.

That is what a patient should get.
That is the standard of care.

There are clinical trials
that are investigating gilteritinib

in combination
with other agents for relapsed and refractory AML.

I always encourage my patients to seek out
a clinical trial because clinical trials

work to try to do better
than the current standard of care.

But a clinical trial
that's that you might be interested

in for FLT3 mutant AML should be one
that incorporates gilteritinib into that trial.

in for FLT3 mutant AML should be one
that incorporates gilteritinib into that trial.

Gilteritinib is an oral agent

that is given

once daily easy to take,
just like taking a Tylenol.

No, no big side effects.

Gilteritinib is approved in the United States 
for patients with relapsed refractory, FLT3

mutated acute myeloid leukemia
based on the results of the ADMIRAL trial.

In general, I believe gilteritinib is well tolerated
by patients with very little GI toxicity

The major toxicity I observe in my own
patients is myelosuppression, which is manageable.